(Q33786434)

29 July 2017

1 reference

title

New treatments for pulmonary fibrosis? (English)

1 reference

29 July 2017

1 reference

J J Egan

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

29 July 2017

1 reference

29 July 2017

volume

354

1 reference

29 July 2017

issue

9193

1 reference

29 July 2017

page(s)

1839-1840

1 reference

Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2900347-5

7 January 2021

Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2900347-5

7 January 2021

Randomised controlled trial comparing prednisolone alone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2900347-5

7 January 2021

A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2900347-5

7 January 2021

Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2900347-5

7 January 2021

Pulmonary fibrosis: cytokines in the balance

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2900347-5

7 January 2021

Survival in patients with cryptogenic fibrosing alveolitis: a population-based cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2900347-5

7 January 2021

The detection of Epstein-Barr virus DNA in lung tissue from patients with idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2900347-5

7 January 2021

Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2900347-5

7 January 2021

An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2900347-5

7 January 2021

Improvement in pulmonary hypertension and hypoxemia during nitric oxide inhalation in a patient with end-stage pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2900347-5

7 January 2021

Caution with use of inhaled nitric oxide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2900347-5

7 January 2021

Assessment of left ventricular diastolic function after single lung transplantation in patients with severe pulmonary hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2900347-5

7 January 2021

Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2900347-5

7 January 2021

Interstitial lung disease clinics for the management of idiopathic pulmonary fibrosis: a potential advantage to patients. Greater Manchester Lung Fibrosis Consortium

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2899%2900347-5

7 January 2021

10.1016/S0140-6736(99)00347-5

Identifiers

DOI

1 reference

29 July 2017

1 reference